Opicapone

Opicapone (BIA 9-1067) is a potent third-generation catechol-O-methyltransferase (COMT) inhibitor for the research of Parkinson's disease and motor fluctuations. Opicapone decreases the ATP content of the cells with an IC50 of 98 μM[1].

Product Specifications

CAS Number

[923287-50-7]

Product Name Alternative

BIA 9-1067

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

COMT

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/opicapone.html

Purity

99.19

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 80°C)

Smiles

CC1=[N+]([O-])C(Cl)=C(C2=NOC(C3=CC([N+]([O-])=O)=C(O)C(O)=C3)=N2)C(C)=C1Cl

Molecular Formula

C15H10Cl2N4O6

Molecular Weight

413.17

Precautions

H302, H315, H319, H335

References & Citations

[1]Bonifácio MJ, et al. Pharmacological profile of Opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat. Br J Pharmacol. 2015 Apr;172 (7) :1739-52.|[2]Ferreira JJ, et al. Opicapone as an adjunct to L-DOPA in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016 Feb;15 (2) :154-165.